Dr. Lazarus is a member of Arkin Holdings’ Pharma Division since 2013. He is a member of the Board of several of its pharmaceutical companies, including Oncorus, Keros Therapeutics and Lutris Pharma. He holds a Ph.D in Molecular Biology and an MBA – both from the Hebrew University of Jerusalem in Israel.
Dr. Yarden brings with her more than 10 years of experience in medical R&D, Biotechnology, business development and Clinical Research. Formerly Dana served as CEO of Omer Therapeutics, Dana also served as the Clinical and BD Affairs Officer at Collplant and before that held multiple functions at BioLineRx. Dana holds an MD and an MBA from The Tel-Aviv University, Israel.
Mr. Hammer is a Partner at Pontifax, a healthcare-dedicated VC fund, where he is in charge of scouting and evaluating new investment opportunities. He currently serves on the Boards of several of Pontifax’s portfolio companies, including Eyevensys, Keros, TargEDys and Zolex. He holds a MS in molecular biology from Tel Aviv University.
Laura will serve as the Chairman of PMatX, and as such as the interface between the venture fund and the lab companies. She is also responsible for Explore Bio, the HC & LS initiative in Israel from Ventures. Having been with Merck for 3 years in various positions and involved in a number of key transactions of M Ventures.
For technology proposals: